

## Intressekonflikter och jävsförbindelser: The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder

Nedan en sammanställning av de självrapporterade intressekonflikter och jävsförbindelser som framkommer hos författarna i det av SVT hänvisade "konsensusdokumentet" från World Federation of ADHD.<sup>1</sup>

\*\*\*\*\*

**S.V.F.** In the past year, he received income, potential income, travel expenses continuing education support and/or research support from, Akili Interactive Labs, Arbor, Genomind, Ironshore, Ondosis, Otsuka, Rhodes, Shire/Takeda, Sunovion, Supernus, Tris, and Vallon. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Alcobra, CogCubed, Eli Lilly, Enzymotec, Janssen, KemPharm, Lundbeck/Takeda, McNeil, Neurolifesciences, Neurovance, Novartis, Pfizer, and Vaya. He also receives royalties from books published by Guilford Press: *Straight Talk about Your Child's Mental Health*; Oxford University Press: *Schizophrenia: The Facts*; and Elsevier: *ADHD: Non-Pharmacologic Interventions*. He is also Program Director of [www.adhdinadults.com](http://www.adhdinadults.com). He is supported by the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 602805, the European Union's Horizon 2020 research and innovation programme under grant agreements Nos. 667302 & 728018 and NIMH grants 5R01MH101519 and U01 MH109536-01.

**T.B.** reports the following financial disclosures in the last 3 years: Advisory/Consultant/Speaker for ADHS digital, Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire/Takeda, Roche, and Infectopharm. Royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press.

**D.C.** reports the following financial disclosures over the last 5 years. Advisory Board: Shire/Takeda, Honoraria and Travel Support: Shire/ Takeda, Medice, Servier, Royalties: Oxford University Press.

**Y.Z.** reports receiving grant funding for research on prevention and control of major chronic non-communicable diseases with Attention Deficit Hyperactivity Disorder in the Ministry of Science and Technology (No: 2016YFC1306100).

**J.B.** is currently receiving research support from the following sources: AACAP, Feinstein Institute for Medical Research, Food & Drug Administration, Genentech, Headspace Inc., NIDA, Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., Tris, and NIH. Dr. Biederman's program has received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Biomarin, Bracket Global, Cogstate, Ingenix, Medavent Prophase, Shire, Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at MGH. In 2020: Through MGH corporate licensing, Dr. Biederman has a US Patent (#14/027,676) for a non-stimulant treatment for ADHD, a US Patent (#10,245,271 B2) on a treatment of impaired cognitive flexibility, and a patent pending (#61/233,686) on a method to prevent stimulant abuse. He receives honoraria from the MGH Psychiatry Academy for tuition-funded CME courses. In 2019, Dr. Biederman was a consultant for Akili, Avekshan, Jazz Pharma, and Shire/Takeda.

He received research support from Lundbeck AS and Neurocentria Inc. Through MGH CTNI, he participated in a scientific advisory board for Supernus.

**M.A.B.** in the last five years has received travel support and speaker fees from Shire Pharmaceuticals. He was on the Scientific Advisory Board of Tali Health, the developers of a cognitive training game for ADHD and other neurodevelopmental disorders. M.A.B. is supported by a Senior Research Fellowship from the National Health and Medical Research Council (NHMRC) of Australia. He is President of the Australian ADHD Professionals Association (AADPA).

**J.H.N.** reports the following financial disclosures in the past three years: is/has been an advisor and/or consultant for Adlon Therapeutics, Akili Interactive, Arbor, Cingulate Therapeutics, Corium, Eisai, Enzymotec, Lundbeck, Medice, Myriad Neuroscience, NLS, OnDosis, Rhodes, Shire/Takeda, and Supernus. He was a DSMB member for Pfizer and Sunovion, received research funds from Enzymotec, Otsuka, Shire and Supernus, and received speaker fees from Shire/Takeda for disease-state presentations.

**M.G.** reports the following financial disclosures: Advisory Boards: Purdue, Takeda, and Janssen.

**N.M.A.** has no conflicts of interest or financial disclosures to report.

**I.M.** reports the following financial disclosures for the last 3 years: Consultant: Novartis Israel, Teva Israel, Medison Ltd. Advisory Board: Teva (2018). Honorariums: Amaoon, Takeda, and MHS virtual summit. She has also received PI funding from Alcobra (S/P), Nuance Ltd.

**L.A.R.** reports the following financial disclosures: he has been a member of the speakers' bureau/advisory board and/or acted as a consultant for Bial, Eli-Lilly, Janssen-Cilag, Medice, Novartis, Pfizer and Shire in the last 3 years. He receives authorship royalties from Oxford Press and ArtMed. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Eli-Lilly, Janssen-Cilag, Novartis, and Shire. He received travel grants from Shire for attending the 2018 APA meetings. He also receives research support from Brazilian government institutions: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), Hospital de Clínicas de Porto Alegre (HCPA), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

**L.Y.** reports the following financial disclosures: has been a member of the speakers' bureau and/or acted as a consultant for Eli-Lilly and Janssen. Has also received grant funding from National Natural Science Foundation of China (81671358, 81873803).

**S.C.** declares reimbursement for travel and accommodation expenses from the Association for Child and Adolescent Central Health (ACAMH) in relation to lectures delivered for ACAMH, Canadian ADHD Alliance Resource (CADDRA), British Association of Psychopharmacology (BAP), and from Healthcare Convention for educational activity on ADHD.

**D.A.** reports the following financial disclosures in the last 3 years: Advisory/consultant/speaker for Shire/Takeda, Janssen and Elvium/ Purdue.

**M.A.S.** has received research support: Supernus, Akilli, Shire. Advisor: Genomind, Shire/Takeda, Cingulate, Eisai.

**T.H.A.** has no conflicts of interest or financial disclosures to report.

**H.F.A.** has no conflicts of interest or financial disclosures to report.

**M.M.J.A.** has no conflicts of interest or financial disclosures to report.

**P.A.** has received honoraria for consultancy to Shire/Takeda, Eli-Lilly and Novartis; educational/research awards from Shire, Lilly, Novartis, Vifor Pharma, GW Pharma and QbTech; speaker at sponsored events for Shire, Lilly, Flynn Pharma and Novartis. He has also received grant funding support from NIHR Biomedical Research Centre (NIHR/ MRC 14/23/17) and NIHR Senior Investigator award (NF-SI-0616- 10040).

**L.A.** has received grant funding from the National Institutes of Health; Broad Institute of MIT and Harvard. Also received funding from Tonix Pharmaceuticals for research on PTSD treatment.

**S.B.** reports the following financial disclosures in the last 3 years: Advisor/consultant/speaker for Medice and Roche. Royalties from Hogrefe, Kohlhammer and UTB.

**J.K.B.** has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.

**C.L.C.** has no conflicts of interest or financial disclosures to report.

**D.D.** reports grants, personal fees and non-financial support from Shire/Takeda. Personal fees and non-financial support from Medice and Eli Lilly. Non-financial support from QbTech. And book royalties from Jessica Kingsley from the self-help version of the New Forest Parenting Programme and fees from the provision of training and supervision for the New Forest Parent Training Programme.

**M.G.** is on the board of the WFADHD.

**S.D.** received research supported by grants from The Lundbeck Foundation (iPSYCH grant no. R248-2017-2003), National Institute of Health (R01, grant no. ES026993), Novo Nordisk Foundation (grant no. 22018), the European Commission (Horizon 2020, grant no. 667302), Tryg Foundation (109399), Helsefonden (grant no. 19-8-0260) and the European Union's Horizon 2020 research and innovation programme under grant agreement No. 847879.

**M.D.** reports the following financial disclosures over the last 3 years: consulting income and research support from Lilly, Medice, Shire, Takeda, and Vifor. He received income as head, supervisor, and lecturer of the School of Child and Adolescent Cognitive Behaviour Therapy at the University Hospital Cologne and as consultant for Child Behaviour Therapy at the National Association of Statutory Health Insurance Physicians (Kassenärztliche Bundesvereinigung). He also received royalties from treatment manuals, books and psychological tests published by Beltz, Elsevier, Enke, Guilford, Hogrefe, Huber, Kohlhammer, Schattauer, Springer, Wiley.

**S.E.** has no conflicts of interest or financial disclosures to report.

**M.F.** has no conflicts of interest or financial disclosures to report.

**B.F.** has received educational speaking fees from Medice. She also received grant funding from the Netherlands Organization for Scientific Research (NWO) Vici Innovation Program (personal grant 016-130-669 to B.F.), European Community Horizon 2020 Programme (H2020/2014 – 2020) under grant agreement no. 667302 (CoCA).

**J.H.** reports the following financial disclosures in the last 3 years: he has received lecture honoraria from Shire, HB Pharma, Takeda, Medice and Biocodex.

**C.A.H.** has no conflicts of interest or financial disclosures to report.

**C.M.H.** has received grant support from the Institutional Development Award (IDeA) from NIGMS.

**S.P.H.** has received book royalties from Oxford University Press and St. Martin's Press, as well as grant support from N.I.H.

**P.J.H.** was member of an advisory board meeting of Takeda.

**C.H.** reports lecture fees and honorarium in 2019 from the British Association of Psychopharmacology (BAP). He has also received funding from the National Institute for Health Research (NIHR); UK Medical Research Council (MRC).

**S.H.K.** reports the following financial disclosures: Akili Interactive (Research Support, Consulting Stock Options), Behavioral Innovations Group (Equity), Bose Corporation (Research Support), Tris Pharma (Research Support), Neos (Research Support), Sana Health (Research Support), OnDosis (Research Support), KemPharm (Research Support). He has also received funding from the NIH, John Templeton Foundation.

**J.J.S.K.** receives research support from Parnassia Groep, the Netherlands.

**J.K.** has given talks at educational events sponsored by Medice; all funds are received by King's College London and used for studies of ADHD.

**H.L.** has served as a speaker for Evolan Pharma and Shire/Takeda and has received research grants from Shire/Takeda; all outside the submitted work.

**T.L.** receives research support from the Joint medical research project of Chongqing Science and Technology Bureau and Health Committee (Key project, Project No.: 2018zdxm012): Chinese research and promotion of Manual for Primary Care Clinicians about the Diagnosis and Treatment of Children with Attention Deficit Hyperactivity Disorder (4th Edition).

**J.L.** has no conflicts of interest or financial disclosures to report.

**J.L.** is a speaker for Eli-Lilly, Janssen, Otsuka and Abbott. Has received some funding for autism research not ADHD.

**E.M.** reports the following financial disclosures in the last 3 years: Advisory/Lecture for: Teva Israel, Medison Ltd. He also received grant support from the Israel Ministry of Health.

**G.M.** has received grant funding from Akili, Alcobra, Alkermes, Allergan, Axsome, Boehringer, Genentech, Jansen, Lundbeck, Medgenics, NLS Pharma, Otsuka, Reckitt Benckiser, Roche, Sage, Shire, Sunovion, Supernus, Takeda, Taisho and Teva.

**P.M.** reports the following financial disclosures: Shire/Takeda speaker's honoraria, advisory board and travel awards.

**S.M.** has no conflicts of interest or financial disclosures to report in the past three years.

**A.Y.M.** has received funding from the Institute of Education Sciences; Michael Smith Foundation for Health Research; Social Sciences and Humanities Research Council of Canada.

**B.S.G.M.** has received grant funding from the National Institutes of Health.

**J.T.N.** has received grant funding support from the National Institute of Mental Health.

**D.P.O.** reports financial disclosures from Shire (advisory board/ speaker fees 2016-2018), travel/accommodation/honoraria from Medice, speaker fees from Otsuka and Janssen, travel/accommodation support from HAC Pharma, scientific committee of a study by Mensia without personal fees.

**O.O.O.** has no conflicts of interest or financial disclosures to report.

**G.V.P.** reports the following financial disclosures: Advisor/consultant/speaker for Takeda, Medice, Ach' e, Novo Nordisk, travel expense for attending AACAP2019 Meeting from Takeda, royalties from Editora Manole. He also received grant funding from São Paulo Research Foundation (FAPESP, grant 2016/22455-8) and National Council for Scientific and Technological Development (CNPq, grant 310582/2017- 2).

**Y.P.** has no conflicts of interest or financial disclosures to report.

**A.S.P.** has received personal fees and non-financial support from Shire/Takeda.

**R.P.R.** has no conflicts of interest or financial disclosures to report.

**A.R.** has no conflicts of interest or financial disclosures to report.

**A.R.** reports the following financial disclosures in the last 3 years: Advisor/consultant/speaker for Medice, Janssen, SAGE, Servier and Shire/Takeda. He has also received grant support from the EC.

**K.R.** has received a grant from Takeda Pharmaceuticals.

**J.R.** has no conflicts of interest or financial disclosures to report.

**M.R.** has received grant funding from the German Federal Ministry of Education and Research (BMBF) Grant 01EE1408.

**J.A.R.Q.** was on the speakers' bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogui, Lundbeck, Almirall, Braingaze, Sincrolab, Medice and Rubi' o in the last 5 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubi' o, Shire, Takeda, Shionogui, Bial, Medice and Eli- Lilly. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 5 years: Eli-Lilly, Lundbeck, Janssen- Cilag, Actelion, Shire, Ferrer, Oryzon, Roche, Psious, and Rubi' o. He also received grant funding from the Department of Health of the Government of Catalonia.

**Arnt S.** has been supported by a Veni Grant from the Dutch Science Organization (ZonMW).

**Anouk S.** has no conflicts of interest or financial disclosures to report.

**R.S.** reports the following financial disclosures for the past 3 years: Sponsorships from Janssen, Lundbeck, Cipla, Dr Reddy and Takeda; Speaker fees from Servier, Sanofi/Zentiva, Janssen, Lundbeck, Lilly, Dr Reddy, Adcock, Novartis and Takeda; Pharmaceutical board membership: Lundbeck, Adcock, Lilly and Mylan.

**J.B.S.** has no conflicts of interest to report and has received salary support the current year from 2R01 MH091068, 1R03 HD087091, R61 MH110043, R01 MH113855, UL1 TR0011860 and 1TL 1TR001861.

**H.S.** has no conflicts of interest or financial disclosures to report.

**M.V.S.** has received grant funding from the National Institute of Health.

**E.S.B.** reports the following financial disclosures over the last three years: MRC, ESRC, Wellcome Trust, The Waterloo Foundation, University of Copenhagen, KU Leuven, Shire/Takeda, Neurtech Solutions, QBTech.

**C.S.** in 2019–2020 reports the following financial disclosures: Lundbeck (Clinical Trial, Departmental Funds), NeuroTech Solutions, Medice (Advisory Board), Rubio (Speaker), Editorial Medica Panamericana (Book Royalties).

**H.C.S.** has no conflicts of interest or financial disclosures to report.

**J.M.S.** reports the following financial disclosures: Advisory Board for Medice; travel support from Medice and Shire/Takeda.

**A.T.** had research funded by Wellcome Trust, MRC, ESRC and Waterloo Foundation.

**G.T.** has no conflicts of interest or financial disclosures to report.

**G.vd.G.** has no conflicts of interest or financial disclosures to report.

**W.v.B** financial disclosures for the last 3 years include: Consultant: Novartis, Indivior, Takeda, Opiant, D&A Pharma; Speaker's Fees: Angelini, Recordati.

**S.V.O.** has no conflicts of interest or financial disclosures to report.

**A.V.** has no conflicts of interest or financial disclosures to report.

**B.V.** has been a consultant for Medice, Lundbeck, Angelini, and Alkermes Pharmaceuticals, and for law firms Goodwin & Procter and Haynes & Boone. He holds no stocks of pharmaceutical companies.

**S.W.** has received in the last 5 years royalties from Thieme Hogrefe, Kohlhammer, Springer, Beltz. Received lecture honoraria from Opopharma in the last 5 years. Her work was supported in the last 5 years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zurich, Switzerland, Bfarm Germany, ZInEP, Hartmann Müller Stiftung, Olga Mayenfisch, Gertrud Thalman Fonds. Outside professional activities and interests are declared under the link of the University of Zurich [www.uzh.ch/prof/ssl-dir/interessenbindungen/client/web](http://www.uzh.ch/prof/ssl-dir/interessenbindungen/client/web).

**Y.W.** receives research support from Sanming Project of Medicine in Shenzhen "The ADHD research group from Peking University Sixth hospital" (SZSM201612036), the Major State Basic Research Development Program of China (973Program, 2014CB846100).

---

<sup>1</sup> Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, Newcorn JH, Gignac M, Al Saud NM, Manor I, Rohde LA, Yang L, Cortese S, Almagor D, Stein MA, Albatti TH, Aljoudi HF, Alqahtani MMJ, Asherson P, Atwoli L, Bölte S, Buitelaar JK, Crunelle CL, Daley D, Dalsgaard S, Döpfner M, Espinet S, Fitzgerald M, Franke B, Gerlach M, Haavik J, Hartman CA, Hartung CM, Hinshaw SP, Hoekstra PJ, Hollis C, Kollins SH, Sandra Kooij JJ, Kuntsi J, Larsson H, Li T, Liu J, Merzon E, Mattingly G, Mattos P, McCarthy S, Mikami AY, Molina BSG, Nigg JT, Purper-Ouakil D, Omigbodun OO, Polanczyk GV, Pollak Y, Poulton AS, Rajkumar RP, Reding A, Reif A, Rubia K, Rucklidge J, Romanos M, Ramos-Quiroga JA, Schellekens A, Scheres A, Schoeman R, Schweitzer JB, Shah H, Solanto MV, Sonuga-Barke E, Soutullo C, Steinhausen HC, Swanson JM, Thapar A, Tripp G, van de Glind G, van den Brink W, Van der Oord S, Venter A, Vitiello B, Walitza S, Wang Y. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. *Neurosci Biobehav Rev.* 2021 Sep;128:789-818. doi: 10.1016/j.neubiorev.2021.01.022. Epub 2021 Feb 4. PMID: 33549739; PMCID: PMC8328933. <https://pubmed.ncbi.nlm.nih.gov/33549739/>.